CosmetaLife clinical trial results could lead to availability of more natural, longer lasting, cost-effective treatment for deep lines and wrinkles by 2009.
St. Paul, Minn. (PRWEB) July 24, 2008 -- Gel-Del Technologies, a St. Paul, Minnesota based biomedical device company announced that it has concluded clinical trials of CosmetaLife, a dermal filler injection that company officials say holds potential to be a more effective alternative to currently available treatments for deep lines and wrinkles that activates a more natural skin correction.
The company began clinical trials of CosmetaLife, a gel-particle product for injection to correct wrinkles, at six U.S. sites in 2006. The company hopes to introduce the product to the rapidly growing $1 billion cosmetic augmentation market in 2009.
David B. Masters, Ph.D., Gel-Del Technologies founder and president, is the inventor of the technology and its related products. Masters said, "It is exciting to see the first human use of this technology over the past 19 months. Based on the results of our 12 month clinical study, CosmetaLife provides a better early performance than hyaluronic acid products, and a lasting effect expected to persist longer due to an actual dermal correction."
Masters continued, "We are pleased with the results of the CosmetaLife trials. As expected, they show our product compares more favorably to Restylane for the first three months and equally to Restylane at the 12-month mark. We are eager to complete the next steps with the FDA."
The proprietary technology used to produce CosmetaLife is covered by 9 U.S. and 26 foreign patents and patent applications
Copyright©2008 Vocus, Inc.
All rights reserved